Ipsen and Marengo Expand Collaboration to Explore New Frontiers in Tumor Immunotherapy
Recently, international pharmaceutical company Ipsen announced that it will further expand its existing collaboration with Marengo Therapeutics, a start-up company in the field of tumor immunotherapy. According to the agreement reached by both parties, Ipsen and Marengo will leverage Marengo's TriSTAR platform to add two new oncology assets to their early-stage development collaboration.
The total amount of the new collaboration is up to $1.2 billion, which includes an upfront payment, as well as milestone payments based on the progress of the collaboration and tiered royalties on sales of the licensed rights. The roots of the collaboration can be traced back to August 2022, when Ipsen acquired the development rights of Marengo's two pre-clinical oncology candidates for over $1.6 billion.
Marengo's proprietary innovative technology platform TriSTAR is capable of precise targeting of the variable Vβ region of T cell receptors, thereby enabling precise activation and directed modulation of specific T cell subsets. This multi-specific antibody fusion technology is expected to overcome the limitations of traditional T cell therapies in terms of poor T cell quality and exhaustion, thereby more broadly activating T cell immune responses, especially for "cold" tumors that are less responsive to traditional treatment approaches.
David Jenkins, Senior Vice President of Research and External Innovation at Ipsen, expressed his genuine pleasure at deepening cooperation with the Marengo team and looked forward to jointly driving the development of innovative cancer treatments with them. Zhu Chen, CEO of Marengo, also expressed his keen expectation of working with Ipsen's oncology team to leverage the TriSTAR platform to tackle the challenges that traditional immunotherapy cannot overcome, bringing new hope to more cancer patients.
We have every reason to believe that, with the combined strengths of both parties in research and resource integration, new cancer immunotherapy solutions will continue to emerge, bringing new hope to patients. We look forward to seeing more exciting developments in this field in the future.
2026-10-16
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
EU Low-Value Parcel Rules Could Disrupt Chemical Sample Flows
-
EU May Build Industry-Level Trade Barriers Against Chinese Chemicals
-
What Can $3.4 Billion Buy? Shin-Etsu Chemical’s Answer: Upstream Control of PVC
-
EU Greenlights Four GM Crops—But Only at the Border
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
Domo Chemicals’ German Subsidiary Insolvencies: Energy Costs, Weak Demand and Chinese Nylon Competition
-
Carbon Fiber’s Price Surge Signals a New Era of Strategic Value—and Supply Tension
-
Sherwin-Williams Surpasses $100 Billion in Market Cap: Is This the ‘Apple Moment’ for Paint, or America’s Industrial ‘One Hundred Years of Solitude’?
-
The Carbon Tollbooth Is Open: EU’s CBAM Ushers in a New Era of Climate-Linked Trade
-
“Anti-Overcapacity” Backfires: China’s Chemical Industry Trapped in a Hell of Its Own Making—and Global Pushback
Recommend Reading
-
EU Authorises Propionic Acid and Its Salts as Feed Additives Until 2035
-
Strides Pharma Reports Strong Q2 as Net Profit Surges 82%
-
"Zipper-Like" Opening and Closing of Hormuz Coupled with Russian Export Ban Send Energy and Chemical Prices Soaring
-
From Painting Walls to Total Collapse: The RMB 152 Million Debt That Tore Off the Last Veil of Asia Chuangneng’s Paint Empire
-
When SWIFT Goes On-Chain: A New 24/7 Order for Cross-Border Payments
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
Polyester Bottle Flakes Market Shows Strong Upward Trend in Recent Two Days
-
Canada Issues Non-Compliance Notice to Dr. Reddy’s on Semaglutide Generic
-
Supply remains generally loose, the acrylonitrile market fluctuates within a range
-
Bayer and Syngenta Score Consecutive Regulatory and Legal Wins in the U.S.